Empagliflozin/metformin extended release - Dong Wha Pharmaceutical
Alternative Names: DW-6014Latest Information Update: 31 May 2023
At a glance
- Originator Dong Wha Pharmaceutical
- Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Cardiovascular therapies; Chlorinated hydrocarbons; Cyclic ethers; Eye disorder therapies; Glucosides; Heart failure therapies; Small molecules; Urologics
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 21 Apr 2023 Dong Wha Pharmaceutical plans a phase I trial for Diabetes mellitus (In volunteers) in South Korea (PO) (NCT05823883)
- 06 Mar 2023 Dong Wha Pharmaceutical completes a phase I trial in diabetes mellitus (In volunteers) in South Korea (PO) (NCT05823870)
- 24 Feb 2023 Phase-I clinical trials in Diabetes mellitus (In volunteers) in South Korea (PO) (NCT05823870)